(Q37680729)

21 August 2017

1 reference

title

Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis (English)

1 reference

21 August 2017

1 reference

Michael Schiff

1

1 reference

21 August 2017

Louis Bessette

series ordinal

2

1 reference

21 August 2017

publication date

23 January 2010

1 reference

21 August 2017

published in

Clinical Rheumatology

1 reference

21 August 2017

volume

29

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

583-591

1 reference

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-009-1363-0

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-009-1363-0

Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-009-1363-0

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-009-1363-0

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

21 January 2018

1 reference

12 December 2020

Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis

1 reference

12 December 2020

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

1 reference

12 December 2020

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

12 December 2020

Comparative overview of safety of the biologics in rheumatoid arthritis

1 reference

12 December 2020

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

1 reference

12 December 2020

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

1 reference

12 December 2020

1 reference

12 December 2020

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

1 reference

12 December 2020

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

1 reference

12 December 2020

The role of novel T cell costimulatory pathways in autoimmunity and transplantation.

1 reference

12 December 2020

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

1 reference

12 December 2020

Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response

1 reference

12 December 2020

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

1 reference

12 December 2020

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

1 reference

12 December 2020

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study

1 reference

12 December 2020

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment

1 reference

12 December 2020

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate

1 reference

12 December 2020

Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists

1 reference

12 December 2020

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

12 December 2020

Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.

1 reference

12 December 2020

Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

1 reference

12 December 2020

10.1007/S10067-009-1363-0

Identifiers

DOI

1 reference

21 August 2017

1 reference